Merzouk H, Bouchenak M, Loukidi B, Madani S, Prost J, Belleville J
Laboratoire de Physiologie Animale, Université de Tlemcen, Tlemcen 13000 Algerie.
J Clin Pathol. 2000 Dec;53(12):917-23. doi: 10.1136/jcp.53.12.917.
To determine the effects of fetal macrosomia related to maternal type 1 diabetes on the lipid transport system.
Serum lipoprotein concentrations and composition and lecithin:cholesterol acyltransferase (LCAT) activity were investigated in macrosomic newborns (mean birth weight, 4650 g; SEM, 90) and their mothers with poorly controlled type 1 diabetes, in appropriate for gestational age newborns (mean birth weight, 3616 g; SEM, 68) and their mothers with well controlled type 1 diabetes, and macrosomic (mean birth weight, 4555 g; SEM, 86) or appropriate for gestational age (mean birth weight, 3290 g; SEM, 45) newborns and their healthy mothers.
In mothers with well controlled type 1 diabetes, serum lipids, apolipoproteins, and lipoproteins were comparable with those of healthy mothers. Similarly, in their infants, these parameters did not differ from those of appropriate for gestational age newborns. Serum triglyceride, very low density lipoprotein (VLDL), apolipoprotein B100 (apo B100), and high density lipoprotein (HDL) triglyceride concentrations were higher, whereas serum apo A-I and HDL3 concentrations were lower in mothers with diabetes and poor glycaemic control than in healthy mothers. Their macrosomic newborns had higher concentrations in all serum lipids and lipoproteins, with high apo A-I and apo B100 values compared with appropriate for gestational age newborns. In macrosomic infants of healthy mothers, there were no significant differences in lipoprotein profiles compared with those of appropriate for gestational age infants. LCAT activity was similar in both groups of mothers and newborns.
Poorly controlled maternal type 1 diabetes and fetal macrosomia were associated with lipoprotein abnormalities. Macrosomic lipoprotein profiles related to poor metabolic control of type 1 diabetes appear to have implications for later metabolic diseases.
确定与母亲1型糖尿病相关的巨大胎儿对脂质转运系统的影响。
对巨大儿(平均出生体重4650克;标准误90)及其母亲患有控制不佳的1型糖尿病、适于胎龄儿(平均出生体重3616克;标准误68)及其母亲患有控制良好的1型糖尿病、巨大儿(平均出生体重4555克;标准误86)或适于胎龄儿(平均出生体重3290克;标准误45)及其健康母亲的血清脂蛋白浓度、组成和卵磷脂胆固醇酰基转移酶(LCAT)活性进行了研究。
在患有控制良好的1型糖尿病的母亲中,血清脂质、载脂蛋白和脂蛋白与健康母亲相当。同样,在她们的婴儿中,这些参数与适于胎龄儿没有差异。与健康母亲相比,患有糖尿病且血糖控制不佳的母亲血清甘油三酯、极低密度脂蛋白(VLDL)、载脂蛋白B100(apo B100)和高密度脂蛋白(HDL)甘油三酯浓度较高,而血清载脂蛋白A-I和HDL3浓度较低。她们的巨大儿所有血清脂质和脂蛋白浓度更高,与适于胎龄儿相比,载脂蛋白A-I和apo B100值较高。在健康母亲的巨大儿中,脂蛋白谱与适于胎龄儿相比无显著差异。两组母亲和新生儿的LCAT活性相似。
母亲1型糖尿病控制不佳和巨大胎儿与脂蛋白异常有关。与1型糖尿病代谢控制不佳相关的巨大儿脂蛋白谱似乎对后期代谢疾病有影响。